2024
Harnessing Institutionally Developed Clinical Targeted Sequencing to Improve Patient Survival in Breast Cancer: A Seven-Year Experience
Koh J, Kim J, Woo G, Yi H, Kwon S, Seo J, Bae J, Kim J, Won J, Ryu H, Jeon Y, Lee D, Kim M, Kim T, Lee K, Kim T, Lee J, Seong M, Kim S, Lee S, Yun H, Song M, Choi J, Kim J, Im S. Harnessing Institutionally Developed Clinical Targeted Sequencing to Improve Patient Survival in Breast Cancer: A Seven-Year Experience. Cancer Research And Treatment 2024, 57: 443-456. PMID: 39164082, PMCID: PMC12016828, DOI: 10.4143/crt.2024.296.Peer-Reviewed Original ResearchConceptsNext-generation sequencingBreast cancerBC patientsHuman epidermal growth factor receptor-2 immunohistochemistryNext-generation sequencing testClinical next-generation sequencingClinical translationAmplification of CCND1Pathogenic/likely pathogenic mutationsOverall survival advantageMetastatic breast cancerNext-generation sequencing analysisPersonalized therapeutic strategiesMulti-gene testingIn situ hybridizationSequencing platformsHigher disease burdenERBB2 amplificationTarget sequenceAsian patientsPatient survivalTargeted therapyPathogenic mutationsSurvival advantagePathogenic alterations
2018
Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal Of Clinical Oncology 2018, 37: 423-438. PMID: 30452337, DOI: 10.1200/jco.18.01160.Peer-Reviewed Original ResearchConceptsAdjuvant endocrine treatmentASCO Clinical Practice GuidelineAdjuvant endocrine therapySecond breast cancerClinical practice guidelinesBreast cancer recurrenceBreast cancerEndocrine treatmentAI treatmentEndocrine therapyExtended therapyCancer recurrencePractice guidelinesHormone receptor-positive breast cancerNode-positive breast cancerNode-negative breast cancerReceptor-positive breast cancerAdjuvant AI therapyNode-positive cancersOverall survival advantageContralateral breast cancerYears of therapyRandomized clinical trialsAromatase inhibitor treatmentAI therapy
2015
Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Zeidan A, Long J, Hall J, Wang R, Huntington S, Abel G, Prebet T, Podoltsev N, Gross C, Gore S, Ma X, Davidoff A. Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS). Blood 2015, 126: 3285. DOI: 10.1182/blood.v126.23.3285.3285.Peer-Reviewed Original ResearchHigh-risk myelodysplastic syndromeHR-MDS patientsKaplan-Meier survival curvesEnd of studyHMA initiationMedian OSClinical trialsComorbidity countHazard ratioHigh school educationClinical practiceMultivariate Cox proportional hazards modelSurvival curvesEnd Results-Medicare databaseMedian household incomeRandomized phase III trialReal-world clinical practiceCox proportional hazards modelOlder MDS patientsDisability Status ScoreRetrospective cohort studyOverall survival advantagePhase III trialsYear of diagnosisErythropoiesis-stimulating agents
2014
Extent of Surgery for Papillary Thyroid Cancer Is Not Associated With Survival
Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, Scheri R, Roman SA, Sosa JA. Extent of Surgery for Papillary Thyroid Cancer Is Not Associated With Survival. Annals Of Surgery 2014, 260: 601-607. PMID: 25203876, PMCID: PMC4532384, DOI: 10.1097/sla.0000000000000925.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerExtent of surgeryTotal thyroidectomyOverall survivalTumor sizeDistant metastasisThyroid cancerSurvival advantagePTC tumorsRadioactive iodine treatmentLarge contemporary cohortOverall survival advantageUnderwent total thyroidectomyProportional hazards modelPresence of nodalMultivariable adjustmentAdult patientsClinical factorsContemporary cohortMultifocal diseaseAbsolute indicationMale sexTumors 1.0Black racePTC patients
2005
Adjuvant therapy for breast cancer.
Hennessy B, Pusztai L. Adjuvant therapy for breast cancer. Minerva Obstetrics And Gynecology 2005, 57: 305-26. PMID: 16166938.Peer-Reviewed Original ResearchConceptsBreast cancerAromatase inhibitorsAdjuvant chemotherapyAdjuvant therapyHormonal therapyHormone receptor-positive breast cancerLymph node-positive breast cancerHormone receptor-positive cancersNode-positive breast cancerReceptor-positive breast cancerAdjuvant chemotherapy regimensAnthracycline-based regimenChemo-therapeutic treatmentsIncorporation of trastuzumabSingle best treatmentAdjuvant hormonal therapyOverall survival advantageUse of trastuzumabDose of cyclophosphamideLarge randomized studiesSchedule of administrationSubset of patientsReceptor-positive cancersRisk of relapseImportant clinical advance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply